Clinical Trial Update: The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating the combination of a PD-1 inhibitor (Sintilimab) with chemotherapy and adaptive radiotherapy for stage III non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: The Third Xiangya Hospital of Central South University | Conditions: NSCLC, Sintilimab | Phase 2 | Status: RECRUITING